asxan.ai Agents Hub

Cognitive Support

Evidence Stack

Brain membrane composition · memory · mitochondrial support

Evidence-first brain health support stack — what the human-evidence record actually shows for the ingredients most associated with cognition, including the positive older-adult-memory signal and the negative established-Alzheimer's trials. This is mechanism and evidence mapping, not medical advice. Cognitive symptoms require physician-led evaluation; discuss any cognitive supplementation with a neurologist or primary care physician. All PubMed identifiers are verified against PubMed before inclusion; cross-market regulatory claims appear verbatim per their authorising authority (FDA · EFSA · ANVISA · TGA).

Last reviewed · How we assess evidence →

Quick Summary

  • Omega-3 DHA supports memory in older adults with mild memory complaints. The Yurko-Mauro 2015 meta-analysis of RCTs concluded DHA alone or DHA+EPA contributes to improved memory function in this population (PMID 25786262). Effects are most consistent on episodic memory and processing speed. See /ingredients/omega-3/, EPA, and DHA.
  • Omega-3 does NOT reverse established Alzheimer's disease. Meta-analyses of RCTs in patients with already-diagnosed Alzheimer's disease (PMID 38924283 from 2024, PMID 28986068 from 2020) do not support cognitive improvement or disease reversal. Do not present omega-3 as a treatment for established dementia.
  • Astaxanthin cognition in healthy adults is unsettled. The Liu 2024 meta-analysis (PMID 38243785) reported significant pooled effects on fatigue and motor function, with cognition a directional trend that did not consistently reach significance.
  • Phosphatidylserine, nervonic acid, and PQQ are scientifically interesting with preliminary / emerging cognitive evidence — mechanistically plausible but not yet backed by confirmatory human cognition trials.
  • This is not medical advice. No supplement on this page treats or prevents Alzheimer's disease, dementia, or any diagnosed cognitive disorder. Discuss cognitive symptoms with a neurologist or primary care physician.

The Evidence Stack

The "evidence" column below describes the strength and direction of the outcome evidence in qualitative terms — well-established, robust, moderate/mixed, preliminary/emerging, or null/negative. The S/A/B/C tier that grades how extensively an ingredient is studied (its evidence volume) lives on each linked ingredient page, not here.

Ingredient Cognitive evidence (qualitative) Key Trial / Meta-analysis asxan.ai page
Omega-3 (DHA / EPA) Robust / well-established for memory in older adults with mild complaints; null/negative for established Alzheimer's disease Yurko-Mauro 2015 PMID 25786262 (memory meta · positive in mild complaints); 2024 meta-analysis PMID 38468309 (healthy adults); PMID 38924283, PMID 28986068 (Alzheimer's null) /ingredients/omega-3/ · EPA · DHA
Astaxanthin Moderate / mixed — fatigue and motor-function signals significant; cognition in healthy adults a directional trend, not consistently significant Liu 2024 PMID 38243785 (11 RCTs n=346 · fatigue and motor significant · cognition NS) /ingredients/astaxanthin/
Phosphatidylserine Preliminary / emerging — membrane-phospholipid mechanism plausible Mechanistic; no confirmatory cognition meta-analysis anchored here /ingredients/phosphatidylserine/
Nervonic Acid Preliminary / emerging — myelin-integrity mechanism plausible; clinical-endpoint translation open Mechanistic; preclinical white-matter interest, clinical endpoints unconfirmed /ingredients/nervonic-acid/
PQQ Preliminary / emerging — mitochondrial-biogenesis mechanism plausible; human cognition evidence limited Mechanistic (PGC-1α biogenesis); human cognition evidence limited /ingredients/pqq/

How It Works

Each ingredient engages brain biology by a different route — DHA through synaptic membrane composition, EPA through eicosanoid balance and mood pathways, astaxanthin as a blood-brain-barrier-crossing mitochondrial antioxidant, phosphatidylserine and nervonic acid through membrane and myelin structure, and PQQ through mitochondrial biogenesis.

DHA — structural component of brain phospholipids. DHA is the dominant long-chain omega-3 fatty acid in brain membrane phospholipids, particularly in synaptic membranes. It supports membrane fluidity, neurotransmitter receptor function, and the metabolic precursors of resolvins and neuroprotectins. The translation from "DHA is structurally essential" to "DHA supplementation improves cognition" is most robust in older adults with mild memory complaints (PMID 25786262) and most negative in established Alzheimer's disease (PMID 38924283). See /ingredients/omega-3/#mechanism for the full mechanism narrative, and the standalone EPA (fish-first; eicosanoid / mood) and DHA (algae first-line; structural) monomer pages.

EPA — eicosanoid-balance and mood pathway. EPA-predominant formulations (EPA ≥60% of total long-chain omega-3) show an antidepressant signal at roughly 1 g/day or below in meta-analyses (PMID 31383846; PMID 26978738). DHA-predominant formulations do not show a clear antidepressant effect. The EPA-vs-DHA distinction matters more in mood than in memory.

Astaxanthin — blood-brain barrier and mitochondrial antioxidant. Astaxanthin crosses the blood-brain barrier in animal models and engages mitochondrial-membrane antioxidant capacity. Translation to human cognitive endpoints in healthy adults remains a directional signal rather than a confirmed clinical-endpoint benefit (Liu 2024 PMID 38243785). The fatigue and motor function signal is more confirmed than the cognition signal.

Phosphatidylserine — membrane phospholipid. PS is a phospholipid component of neuronal membranes; the supplement-trial literature includes cognitive aging and stress-response contexts. Treat the mechanism as biologically plausible but not yet backed by confirmatory cognition trials.

Nervonic acid — myelin sheath integrity. Nervonic acid (cis-15-tetracosenoic acid) is a long-chain monounsaturated fatty acid enriched in myelin sphingolipids. Mechanistic interest in white-matter integrity is established preclinically; clinical-endpoint translation remains the open question.

PQQ — mitochondrial biogenesis. Pyrroloquinoline quinone is a quinone cofactor researched in mitochondrial biogenesis pathways (PGC-1α). The clinical evidence base in human cognition is limited.

DHA and depression — EPA-vs-DHA distinction (mood overlap). The Mocking 2016 meta-regression (PMID 26978738) and Liao 2019 meta (PMID 31383846) consistently found that the antidepressant signal in omega-3 meta-analyses is driven by EPA-predominant formulations (EPA ≥60% of total long-chain omega-3) at roughly ≤1 g/day, not by DHA-predominant formulations. This mood-vs-memory distinction is one of the few evidence-graded product-selection decisions in the omega-3 literature and is worth preserving when reading cognitive-support coverage.

Choline and brain development (life-stage cross-link). The Caudill 2018 RCT (PMID 29217669) reported maternal choline supplementation at 930 mg/day during the third trimester improved infant information-processing speed at 4, 7, 10, and 13 months. This is brain-development context, not adult-cognition context — it is referenced here to anchor the membrane-phospholipid (choline-containing phosphatidylcholine and phosphatidylserine) mechanism cluster as biologically meaningful, while keeping the audience boundary explicit. See /lifestyles/pregnancy/ for the pregnancy-specific framing.

Established Alzheimer's disease — negative-trial cluster. The Yurko-Mauro 2015 meta (PMID 25786262) defines the older-adult-with-mild-complaint cohort where DHA shows benefit. The Araya-Quintanilla 2020 SR (PMID 28986068) and Martinez 2024 meta (PMID 38924283) document the null result in already-diagnosed Alzheimer's disease. The two cohorts produce opposite-signed evidence; reading either in isolation is misleading.

Body systems engaged: Neurological & Cognitive · Mitochondrial & Cellular Energy. Mechanism tags: Neurotransmitter modulation · Autophagy / Mitophagy · Free radical scavenging.

What the Trials Show — Including the Nulls

Astaxanthin is not a cognitive enhancement supplement. The Liu 2024 meta-analysis (PMID 38243785) described cognition in healthy adults as a directional trend that did not consistently reach statistical significance across the included trials. The fatigue and motor function signal is more confirmed than the cognition signal — but neither rises to "cognitive enhancement" claim level.

The "cognitive enhancement" category is more saturated with overstated claims than the supplement evidence supports. This includes nootropic-positioned ingredients (phosphatidylserine, nervonic acid, PQQ) whose human cognition evidence remains preliminary / emerging. Read each ingredient on its own evidence merits.

Cognitive symptoms in adulthood warrant medical evaluation, not supplementation alone. Acute or progressive memory complaints, executive function decline, or behavioral change should be discussed with a primary care physician and, where appropriate, a neurologist.

Ginkgo biloba does not prevent cognitive decline or dementia in older adults. The Snitz 2009 JAMA randomized trial (PMID 20040554), part of the Ginkgo Evaluation of Memory (GEM) study, randomized 3,069 community-dwelling adults aged 72 to 96 to 120 mg twice daily of Ginkgo biloba extract vs placebo for a median 6.1 years. There was no significant difference in change on standardized cognitive function tests of memory, attention, visual-spatial construction, language, or executive function. Ginkgo is not on the asxan.ai related-ingredients list for this page, and is referenced here only to anchor the negative-evidence framing — popular nootropic positioning does not change the trial-level result.

"Multi-domain dementia-prevention" frameworks are not interchangeable with supplement marketing. Multi-domain lifestyle intervention trials in older adults at risk for cognitive decline have produced mixed but partially positive results; these are intensive structured programs (diet, exercise, cognitive training, vascular risk management), not single-ingredient supplementation. Do not present any combination of supplements on this page as equivalent to a multi-domain clinical intervention.

Stacking & Timeline

Mechanistic pairings are plausible but rarely backed by head-to-head synergy trials; realistic timelines run from weeks (mood signal in EPA-predominant formulations) to months (memory benefit in older adults with mild complaints), and lifespan-scale trajectories cannot be inferred from any single supplement RCT.

Mechanistic pairs

DHA + EPA · membrane and eicosanoid pair. DHA serves the structural-membrane angle; EPA serves the eicosanoid-balance and mood angle. Most commercial fish-oil and algae oil products provide both. The supplemental-form distinction (EPA-predominant for mood vs DHA-predominant for memory) is one of the few evidence-driven product-selection decisions in the omega-3 literature.

Omega-3 + Astaxanthin · membrane-antioxidant pair (mechanism only). DHA contributes to membrane composition; astaxanthin contributes to membrane antioxidant capacity. No head-to-head clinical synergy trial in cognition.

Phosphatidylserine + DHA · membrane composition pair (mechanism only). PS is a phospholipid; DHA is the dominant fatty acid in neuronal membrane phospholipids. The mechanistic logic is direct; clinical-endpoint synergy in humans is not yet confirmed by trials.

When to see results — realistic timeframes

4 to 8 weeks · mood signal in EPA-predominant formulations. Meta-analyses (PMID 31383846, PMID 26978738) typically pool trials in the 4 to 12 week range; early signal can appear by week 4 in some trials, with the pooled effect size most robust by week 8.

12 to 24 weeks · memory benefit in older adults with mild complaints. The Yurko-Mauro 2015 meta-analysis (PMID 25786262) pooled trials predominantly at 12 to 24 weeks; the effect size on episodic memory is modest but consistent.

12 weeks · fatigue and motor function (astaxanthin). The Liu 2024 meta-analysis (PMID 38243785) pooled 11 RCTs typically at 6 to 24 mg/day for 8 to 12 weeks.

Lifespan-scale cognition trajectories cannot be inferred from any single supplement RCT. Treat ingredient-level signals as biomarker and mid-term function evidence, not as guarantees about long-run cognitive trajectory.

  • Longevity Stack — mitochondrial-antioxidant and NAD+ pathway overlap; astaxanthin and omega-3 reappear there.
  • Heart Health — DHA cardiovascular evidence and the EPA-vs-DHA distinction are the shared anchor.
  • Senior 60+ — life-stage page where the older-adult mild-memory-complaint cohort (Yurko-Mauro 2015) is most directly relevant.
  • High-Stress Lifestyle — phosphatidylserine and EPA-predominant omega-3 mood-pathway overlap.

Deep-dive long-form evidence reading

For deep-dive narrative across the cognitive-support evidence base (NAD+-axis cognition RCTs + omega-3 DHA cognitive chronology + NADH historical cognition data), see the dedicated evidence articles:

  • 25 Years of NAD+ Clinical Evidence — NR-MCI trial (Orr 2024 PMID 37994989) + niacin / NMN historical cognition + citation corrections in the cognition cluster.
  • Omega-3 Evidence History — DHA brain membrane composition + VITAL-Cognition (Kang 2022 PMID 35415212) + Yurko-Mauro 2015 meta + Cochrane Alzheimer's nulls.
  • Reduced NADH vs NMNH — NADH jet-lag cognition (Birkmayer 2002 PMID 12399028) + CFS cognitive symptom evidence (Forsyth 1999 PMID 10071523).

Cross-reading these three evidence articles alongside this cognitive-support goal page builds the holistic cognitive evidence picture from NAD+ precursor mechanism → DHA structural foundation → historical NADH cognition signals.

Frequently Asked Questions

1. Does omega-3 prevent or treat Alzheimer's disease?

No. DHA supports memory in older adults with mild memory complaints (meta-analysis PMID 25786262), but randomized trials in patients with already-diagnosed Alzheimer's disease do not show cognitive improvement or disease reversal from omega-3 supplementation (PMID 38924283, PMID 28986068). Omega-3 should be presented as part of cognitive maintenance across the lifespan, not as a treatment for established dementia.

2. EPA-predominant or DHA-predominant for cognition?

For memory in older adults, DHA-containing formulations (DHA alone or DHA+EPA) carry the meta-analytic signal (PMID 25786262). For mood and depressive symptoms, EPA-predominant formulations (≥60% EPA) carry the antidepressant signal (PMID 31383846, PMID 26978738). The choice depends on goal; many commercial fish-oil products contain both in varying ratios.

3. Is astaxanthin a "nootropic"?

The marketing language "nootropic" is not an evidence-graded category. Astaxanthin has well-established evidence for skin and fatigue, partial signals for cardiovascular markers, and an unsettled directional trend for cognition in healthy adults (PMID 38243785). The honest framing is "carotenoid antioxidant with cross-domain biomarker engagement and a not-yet-confirmed cognition signal," not "cognitive enhancer."

4. What about creatine, L-theanine, or caffeine for cognition?

Creatine, L-theanine, and caffeine are not currently on this page's related-ingredients list. They are reasonable future additions to the cognitive-support stack; the References & Coverage Notes section tracks these gaps.

5. What about Ginkgo biloba — does it prevent dementia?

No. The Snitz 2009 JAMA trial (PMID 20040554) — part of the Ginkgo Evaluation of Memory (GEM) study — randomized 3,069 community-dwelling adults aged 72 to 96 to 120 mg of Ginkgo biloba extract twice daily vs placebo for a median 6.1 years. There was no significant effect on memory, attention, visual-spatial construction, language, or executive function. Ginkgo is not on the asxan.ai cognitive-support related-ingredients list because of this and adjacent null evidence. Popular nootropic positioning does not change the trial-level result.

6. EPA-predominant for depression, DHA-predominant for memory — does this hold up?

Yes — this is one of the better-supported product-selection distinctions in the omega-3 literature. The Mocking 2016 meta-regression (PMID 26978738) and Liao 2019 meta (PMID 31383846) consistently find the antidepressant signal is driven by EPA-predominant formulations (EPA ≥60% of total long-chain omega-3) at roughly ≤1 g/day. The Yurko-Mauro 2015 meta (PMID 25786262) supports DHA-containing formulations for memory in older adults with mild complaints. Many commercial fish-oil and algae oil products provide both — checking the EPA-to-DHA ratio on the supplement facts panel matters more than checking the total dose in isolation.

7. Is maternal choline supplementation a cognitive-support intervention for the mother or the infant?

Caudill 2018 (PMID 29217669) is specifically about infant information-processing speed at 4, 7, 10, and 13 months following maternal supplementation at 930 mg/day of choline during the third trimester — it is a brain-development trial, not an adult-cognition trial. The relevance to this page is mechanistic — phosphatidylcholine and phosphatidylserine are membrane phospholipids — not as a recommendation for non-pregnant adults to take 930 mg/day of choline for their own cognition. See /lifestyles/pregnancy/ for the pregnancy-specific framing and the obstetric-care-team boundary.

References

All PMIDs verified against PubMed. Effect sizes are reported as published.

  1. PMID 25786262 · Yurko-Mauro 2015 · DHA memory meta-analysis · DHA alone or DHA+EPA improves memory in older adults with mild memory complaints (episodic memory, processing speed)
  2. PMID 38468309 · 2024 meta-analysis · omega-3 cognition in healthy adults
  3. PMID 38924283 · Martinez 2024 · omega-3 in established Alzheimer's disease · null (no cognitive improvement or disease reversal)
  4. PMID 28986068 · Araya-Quintanilla 2020 · systematic review · omega-3 in diagnosed Alzheimer's disease · null
  5. PMID 38243785 · Liu 2024 · astaxanthin meta-analysis (11 RCTs, n=346) · fatigue and motor function significant · cognition non-significant directional trend
  6. PMID 31383846 · Liao 2019 · omega-3 antidepressant meta · EPA-predominant (≥60% EPA) signal at ≤1 g/day
  7. PMID 26978738 · Mocking 2016 · omega-3 antidepressant meta-regression · EPA-predominant formulations drive the signal
  8. PMID 29217669 · Caudill 2018 · maternal choline RCT · 930 mg/day third trimester improved infant information-processing speed (brain-development cross-link)
  9. PMID 20040554 · Snitz 2009 · JAMA · Ginkgo Evaluation of Memory (GEM) · 120 mg twice daily, median 6.1 y · no cognitive-decline prevention (negative-evidence anchor)
  10. PMID 37994989 · Orr 2024 · NR-MCI trial (NAD+ axis cognition cross-link)
  11. PMID 35415212 · Kang 2022 · VITAL-Cognition (omega-3 DHA cognitive chronology cross-link)
  12. PMID 12399028 · Birkmayer 2002 · NADH jet-lag cognition (cross-link context)
  13. PMID 10071523 · Forsyth 1999 · NADH chronic-fatigue-syndrome cognitive symptom evidence (cross-link context)

Coverage Notes

This Cognitive Support page draws from five linked ingredient pages: omega-3, astaxanthin, phosphatidylserine, nervonic acid, and PQQ. Omega-3 and astaxanthin carry confirmatory human meta-analyses (PMIDs cited above); phosphatidylserine, nervonic acid, and PQQ are described qualitatively as preliminary / emerging in the evidence stack and treated as mechanism candidates in How It Works, rather than fabricating PMID citations that the human cognition evidence does not yet support. Additional cognition-relevant ingredients (L-theanine, creatine, caffeine) are not currently in the related-ingredients list — they are reasonable future additions.

← Home

Ask Agent Axor